Released May 13, 2024, before the open
10-Q filed May 13, 2024, 43 days after period end · 0001171843-24-002785
Q1 2024 · 10-Q
Revenue—
Net Income-$10.79M-$10.79M N/M vs Q1 2023N/M vs Q4 2023
EPS, diluted—
Operating Income-$12,770,000N/M
Operating Cash Flow-$13,888,000N/M
Free Cash Flowderived-$13,888,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$10.79M | -$7.84M | -$7.16M | -$7.42M |
| EPS Diluted | — | — | -$0.07 | -$0.14 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR